EACS. 2007: Guidelines for the clinical management and treatment of HIV infected adults in Europe. URL: http://www.eacs.eu/guide/index.htm Gallant JE, Staszewski S, Pozniak AL, et al. 2004. Efﬁcacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA, 292:191–201. Gallant JE, Parish MA, Keruly JC, et al. 2005. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis, 40:1194–8. Gallant JE, DeJesus E, Arribas JR et al. 2006. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med, 354:251–60. Gallo RC, Salahuddin SZ, Popovic M, et al. 1984. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science, 224:500–3. Gulick RM, Mellors JW, Havlir D, et al. 2000. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med, 133:35–9. Izzedine H, Hulot JS, Vittecoq D, et al. 2005. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled mul- ticentre study. Nephrol Dial Transplant, 20:743–6. Julg BD, Bogner JR, Crispin A, et al. 2005. Progression of renal impairment under therapy with tenofovir. AIDS, 19:1332–3. Llibre JM, Domingo P, Palacios R, et al. 2006. Group Sustained improve- ment of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS, 20:1407–14. Lochet P, Peyriere H, Lotthe A, et al. 2003. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med, 4:62–6. Margot NA, Lu B, Cheng A, et al. 2006. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med, 7:442–50. Moyle GJ, Sabin CA, Cartledge J, et al. 2006. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine ana- logue in persons with lipoatrophy. AIDS, 20:2043–50. Muro E, Droste JA, Hofstede HT, et al. 2005. Nevirapine plasma concen- trations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Deﬁc Syndr, 39:419–21. NIH: The Panel on Clinical Practices for Treatment of HIV Infection. 2006. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2006. URL: http://AIDSinfo.nih.gov Pozniak AL, Gallant JE, DeJesus E, et al. 2006. Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/ Lamivudine and Efavirenz in Antiretroviral-Naïve Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis. J Acquir Immune Deﬁc Syndr, 43:535–40. Atripla™ – HIV therapy in one pill Riddler SA, Haubrich R, Dirienzo G, et al. 2006: A prospective, randomized, Phase III trial of NRTI-, PI-, NNRTI-sparing regimens for initial treat- ment of HIV-1 infection – ACTG 5142. In: 16th International AIDS Conference. Toronto, Canada (2006). Robbins GK, De Gruttola V, Shafer RW et al. 2003. Comparison of sequen- tial three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med, 349(24):2293–303. Rousseau FS, Wakeford C, Mommeja-Marin H, et al. 2003. Prospective randomized trial of emtricitabine versus lamivudine short-term mono- therapy in human immunodeﬁciency virus-infected patients. J Infect Dis, 188:1652–8. Saag MS, Cahn P, Rafﬁ F, et al. 2004. Efﬁcacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA, 292:180–9. Sanne I, Quinn JB, Harris J, et al. 2002. Genotypic analysis of HIV-1 infected ART-naive patients receiving emtricitabine (FTC) or lamivudine (3TC) in a double blind equivalence trial. XIV International AIDS Conference, Barcelona. Abs TuPeB4433. Schmid H, Mühlbayer D, Röling J, et al. 2006. Macroenzyme creatine kinase (CK) type 2 in HIV-infected patients is signiﬁcantly associated with TDF and consists of ubiquitous mitochondrial CK. Antiv Ther, 11:1071–80. Schooley RT, Ruane P, Myers RA, et al. 2002. Tenofovir DF in antiret- roviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS, 16:1257–63. Shafer RW, Smeaton LM, Robbins GK, et al. 2003. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med, 349:2304–15. Squires K, Pozniak AL, Pierone G, et al. 2003. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. Ann Int Med, 139:313–20. Squires K, Lazzarin A, Gatell JM, et al. 2004. Comparison of once-daily atazanavir with efavirenz, each in combination with ﬁxed-dose zidovu- dine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Deﬁc Syndr, 36:1011–9. Staszewski S, Morales-Ramirez J, Tashima KT, et al. 1999. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med, 341:1865–73. Zuger A. 2006. Report from the XVI International AIDS Conference. ACTG 5142 compares class-sparing regimens in treatment-naive patients. AIDS Clin Care, 18:98. Therapeutics and Clinical Risk Management 2008:4(4) 577